effects of pomegranate juice consumption in inflammatory factors( hs-CRP; ICAM; VCAM; IL-6; E-Selectin ) and blood pressure and endothelial function evaluation (FMD) in hypertensive patients

short-and long term effects of pomegranate juice consumption in inflammatory factors( hs-CRP; ICAM; VCAM; IL-6; E-Selectin ) and blood pressure and endothelial function evaluation (FMD) in hypertensive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206249662N4

Enrollment

Registered

2012-08-09

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Blood pressure. Condition 2: flow-mediated dilatation (FMD). Hypertensive diseases Diseases of arteries, arterioles and capillaries

Interventions

Intervention 1: In group 1(case)15 hypertensive patients, 150 ml consumption of fresh Pomegranate juice. once a day between launch to dinner for 2 weeks. Intervention 2: In group 2(Control)15 hypert

Treatment - Drugs

In group 1(case)15 hypertensive patients, 150 ml consumption of fresh Pomegranate juice. once a day between launch to dinner for 2 weeks.

In group 2(Control)15 hypertensive patients, 150 ml consumption of Water for 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: hypertensive patients whit :BMI more than 18 and less than 35kg/m2 ; Systolic blood pressure (SBP) more than 100 and less than 160 mm Hg; Diastolic blood pressure (DBP) more than 50 and less than 100 mm Hg Exclusion criteria: Individuals with a history of diseases; diabetes; cardiovascular disease; liver and kidney as well as those with thyroid disease; pregnant and breastfeeding; metabolic and endocrine diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Positive changes in inflammatory markers. Timepoint: Baseline and after 2 weeks. Method of measurement: ELISA kit.;Positive changes in endothelial function. Timepoint: Baseline and after 2weeks. Method of measurement: Doppler ultrasonography.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: Baseline and after 2 weeks. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 2 weeks. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after 2 weeks. Method of measurement: KIT.;HDL Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;LDL level. Timepoint: Before and after 2weeks. Method of measurement: KIT.	—

Measure

Time frame

Blood pressure. Timepoint: Baseline and after 2 weeks. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 2 weeks. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after 2 weeks. Method of measurement: KIT.;HDL Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;LDL level. Timepoint: Before and after 2weeks. Method of measurement: KIT.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026